@article{d79045012d18403c86546d70319435e3,
title = "Treatment threshold for neonatal hypoglycemia",
author = "Thornton, \{Paul S.\} and \{de Leon\}, \{Diva D.\} and Sperling, \{Mark A.\}",
note = "Funding Information: Dr. Thornton reports receiving research funding from Zealand Pharma, Ascendis Pharmaceuticals, and Opko Biologics and consulting fees from Xeris Pharmaceuticals; Dr. De Leon, receiving research support from Zealand Pharma and Crinetics Pharmaceuticals, consulting fees from Zealand Pharma, Crinetics Pharmaceuticals, Soleno Therapeutics, Triangle Insights Group, and Slingshot Insights and owning stock in Merck; and Dr. Sperling, serving on the Insulin Advisory Board for Novo Nordisk. No other potential conflict of interest relevant to this letter was reported.",
year = "2020",
month = jun,
day = "4",
doi = "10.1056/NEJMc2004233",
language = "English",
volume = "382",
pages = "2272",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "23",
}